

Vimta Labs Limited

Investor Presentation Q1FY24

### Disclaimer



The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global industries that we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Vimta Labs Ltd.

# Contents

Q1FY24 Earnings

Company Overview

Industry Landscape

Our Competitive Advantage

Way Forward





# Q1FY24 Earnings

- Q1FY24 Highlights
- Key Metrics: Q1FY24
- Profit & Loss Statement
- Financial Track Record
- Shareholding Pattern

)1

## Q1FY24 Highlights




### **Earnings Highlights**

- Total Income for Q1FY24 were at Rs. 841 Mn
- ➤ EBITDA for Q1FY24 was Rs. 252 Mn; EBITDA margin remained steady at 30.0%
- > Q1FY24 PAT was at Rs. 122 Mn; PAT margin for the quarter was at 14.5%
- ➤ Basic EPS was at Rs. 5.5 in Q1FY24 against Rs. 5.4 in Q1FY23
- > Total Debt as of 30<sup>th</sup> June stood at Rs. 137 Mn down from Rs. 150 Mn as of 31<sup>st</sup> March 2023
- > Cash and Cash equivalents were at Rs. 285 Mn as of 30<sup>th</sup> June 2023
- > Q1FY24 Capex was at Rs 218 Mn
- > Debt to Equity ratio was 0.05x

## **Key Metrics: Q1FY24**






## **Profit & Loss Statement**





			,,	
Particulars (₹ Mn)	Q1 FY24	Q1 FY23	Q4 FY23	
Revenue from Operations	835	791	818	
Other Income	6	9	7	
Total Income	841	800	825	
Material and Testing Costs	204	190	188	
Cost of lab setup	2	3	1	
Changes in inventories of work-in-progress	0	0	1	
Employee benefits expense	247	227	220	
Other expenses	136	132	167	
Total Expenses	588	552	576	
EBIDTA (including Other income)	252	248	248	
EBIDTA (%)	30.0%	31.0%	30.1%	
Finance costs	4	9	2	
Depreciation expense	85	73	80	
Exceptional Items	0	0	0	
Profit before tax	163	166	166	
PBT (%)	19.4%	20.7%	20.1%	
Tax	41	46	39	
Profit for the year	122	120	127	
PAT (%)	14.5%	15.0%	15.4%	
Basic EPS (INR)	5.5	5.4	5.7	
Diluted EPS (INR)	5.4	5.3	5.6	

### Financial Track Record










# **Shareholding Pattern**



### Vimta Labs Shareholding as on 30<sup>th</sup> June 2023



Share Information (as on 30 <sup>th</sup> June 2023)		
NSE Ticker	VIMTALABS	
BSE Ticker	524394	
Market Cap (INR Cr)	905	
% free-float	62.8%	
Free-float market cap (INR Cr)	568	
Total Debt (INR Mn)	137	
Cash & Cash Equivalents (INR Mn)	285	
Shares Outstanding	2,21,38,549	
3M ADTV (Shares)*	60,893	
3M ADTV (INR Cr)*	2.38	
Industry	TIC	

<sup>\*</sup>Source: NSE & BSE



# Company Overview

- Vimta Labs at a Glance
- Our Journey
- Services
- Geographical Presence
- Management
- Accreditation

)2

### Vimta Labs at a Glance



Established in 1984, VIMTA is one of India's most renowned companies for contract research and testing, recognized for its high quality, cutting edge technology enabled wide spectrum, reliable services and vast experience. The company's broad capabilities span across biologics, small molecules, agro-chemicals, food & beverages, electronics, clinical diagnostics, medical devices, home and personal care products, and environment testing.



Of experience in CRTO industry

1,400+

Dedicated Multi Disciplinary Team

19

Regional & Satellite labs across India

400,000+

Sq.ft. of Ultra modern lab space


75+

Successful Regulatory Audits

#1


In India:

- Pharma Analytical & Preclinical Services
- > Food Testing Services



## Our Journey





<sup>•</sup> Investment & Revenues in INR

<sup>•</sup> Investments depicted may have spread across more than the denoted year

# Our Offerings (1/3)



Drug discovery and development support to Lifesciences Industry

Food & Agriculture Services

**Electronics & Electricals Testing** 

**Clinical Diagnostics** 

**Environment Testing** & Consultancy

Offerings

Industry

Accreditations & Regulatory Approvals

Pharma Analytical

Pharmaceuticals

Clinical Research

Pharmaceuticals

DCGI, USFDA, WHO, NPRA, UK MHRA and other European countries

Services

- Leader in India for a wide range of analytical services for the pharmaceutical, biopharmaceutical and animal health industries.
- E&L studies
- Stability testing
- Validations
- Genotoxic impurities
- Elemental analysis
- > In vitro studies

- Physical characterization
- Method development: > Dissolution testing
  - Microbiology
  - > Immunogenicity
  - Characterization
  - Bioassays

- > One of India's most reputed and reliable CROs
- > Experience of over 2,000 clinical
- > Impressive track record of successful global regulatory audits from national and international regulatory authorities.

- **Preclinical Support**
- Pharmaceuticals, Biotech, Medical device, Agrochemicals

Good Laboratory Practices (GLP) certified by NGCMA, and AAALAC accredited

- > General and Genetic toxicology
- > Safety pharmacology
- > Development and Reproductive Toxicology (DART) studies
- > Immunotoxicology
- Comprehensive pharmacological and drug metabolism and pharmacokinetic
- > Wide gamut of Toxicology services also support agrochemical and medical device industries

# Our Offerings (2/3)



Drug discovery and development support to Lifesciences Industry

Food & Agriculture Services

Electronics & Electricals Testing

**Clinical Diagnostics** 

Environment Testing & Consultancy

-			<del>-</del>
	Offerings	Food Testing	Electronics & Electricals Testing
	No. of Laboratories	8	1
	Accreditations & Regulatory Approvals	FSSAI, NABL, BIS, APEDA, EIC, Spices Board	ISO 17025 accredited by NABL and approved by TEC
	Services	<ul> <li>VIMTA is a 'National Referral Lab' and a preferred laboratory partner for many MNCs, and also relied on by Government institutes for projects of national importance</li> <li>Routine as well as specialized testing services for food and agriculture products to assist with R&amp;D, regulatory compliance, trade and internal quality requirements</li> <li>Support new product development, and offer multifarious analytical services for:         <ul> <li>The feed that sustains animal life</li> <li>Crops yielded by various soils</li> <li>All varieties of food and food products for consumption/export</li> <li>Milk, water and beverages</li> <li>Nutraceuticals</li> </ul> </li> </ul>	<ul> <li>Newly launched EMI / EMC services cater to IT, automotive, aviation &amp; defence, medical devices, telecom, home appliance / consumer electronics and allied industries</li> <li>Services provided are EMI / EMC TESTING, Radiated, Conducted, Environmental testing, Mechanical &amp; electrical safety testing, Performance testing, Product certification</li> <li>The non EMI / EMC services are rendered through our wholly owned subsidiary, Emtac Laboratories Pvt. Ltd</li> </ul>

# Our Offerings (3/3)



Drug discovery and development support to Lifesciences Industry

Food & Agriculture
Services

Electronics & Electricals Testing

**Clinical Diagnostics** 

Environment Testing & Consultancy

### Offerings

No. of Laboratories

Accreditations & Regulatory Approvals

Services

### **Clinical Diagnostics**

2 (regional reference laboratories); 6 (branch laboratories)

ISO 15189 by NABL, CAP

- > Strong brand equity and a pan India presence offering both routine and specialized diagnostic services
- ➤ The hallmarks of our clinical diagnostics services are stringent quality systems, latest technologies and committed customer care
- > Clinical diagnostics range:
  - Biochemistry
  - > Haematology
  - Molecular biology
  - Microbiology
  - Histopathology / Cytopathology
  - Serology
  - Cytogenetics

### **Environment Testing & Consultancy**

NA

MoEF, ISO 17025 by NABL, QCI/NABET, OSHAS 45000

- Environment Impact Assessments and Environment Testing since inception. Provide our services to various industries such as power, infrastructure, steel, cement, oil & gas, mining, pharmaceutical, food, chemical etc.
- > Our Services:
  - Testing of water, waste water, air, soil, noise
  - Post-project monitoring, environment compliance studies
  - > EIA & social impact assessments
  - > Deep-ocean studies, marine ecological studies
  - > Forestry and ecological studies
  - Rejuvenation & clean-up consultancy

- Ground water studies & contamination studies
- > Site due diligence, remediation strategies
- Social sustainability, climate change and environmental education projects
- Mining plan preparation
- > EHS audits
- Work space monitoring etc.
- Green Audit

# **Geographical Presence**



Headquartered in Hyderabad, VIMTA has 19 laboratories across India, with a total laboratory space of over 400,000 sq. ft.





Clinical Diagnostics



▲ Electronics & Electrical

Environment

### ★ Food

Ahmedabad

Noida

Mumbai (NFL)

Pune

Bengaluru

Visakhapatnam

Nellore

### Environment


Coimbatore

Noida

Kolkata

### Clinical Diagnostics

Chennai Bhubaneswar Delhi Visakhapatnam Varanasi Vijayawada Kolkata Tirupati



# Key Management Team





S P Vasireddi Executive Chairman

Dr. S P Vasireddi is a Scientist - Technocrat - Entrepreneur having more than 45 years of experience in contract research and testing laboratory management. He is the founder and Chairman of VIMTA.

Dr. Vasireddi is reckoned as the pioneer of CRO industry in India. He led VIMTA from a single bench laboratory to a wide spectrum, globally recognized CRTO. In recognition of his eminence in CRO & Testing industry he is/has been nominated as a member on the Advisory/ Governing Boards of several apex scientific and regulatory bodies of the country such as FSSAI, NABL etc.



Harita Vasireddi Managing Director

Harita has close to 25 years of experience in the TIC/CRO industry with track record of growth and profitability.

Her Core competencies include management & driving organizational adaptabilty and development, quality management systems, and risk management.

She holds an MBA in Operations Management from Boston College, USA; and is a B.Pharm graduate from Mysore university, India



Sreenivas Neerukonda Executive Director

Sreenivas's core competencies include strategic planning and execution, new service opportunities development, communication and relationship building, competitive intelligence, and fostering strong team relations to deliver goal oriented performance.

He holds an MBA in Management Information Systems, University of Oklahoma, USA; B.Pharm, Nagpur University, India.

## Key Management Team (Cont'd)





Harriman Vungal Executive Director - Operations

Harriman was inducted to the Board as one of the Promoter Directors in 1990 and was appointed as Technical Director of the Company in 1992. He has extensive lab operations management experience and is a go to senior resource on GXPs.

He has led the Company's effort in building state of the art IT infrastructure, systems and their compliance to applicable regulations.

He holds D. Tech in Electronics from Toronto, Canada.



Suresh Kumar President

Suresh have more than two decades of experience in Testing, Inspection, Certification and Contract Research Organization with diversified products and industries.

He was with TUV SUD South Asia as Chief Operating Officer and Member of Board of Management before Joining VIMTA

He holds B.Sc (Tech) from ICT Mumbai and B.Sc (Polymer Chemistry) from Kerala university.



Narahari Naidu D.R. Chief Financial Officer

Narahari has close to 15 years of experience in diversified industries.

His core competencies include Financial Planning, Corporate Strategy, Fund raising, Banking & Treasury, Taxation, Investor Relations, Enterprise Risk Management, Compliance & Governance, Financial Reporting & Audit, Procurement Strategies.

He is a Chartered Accountant (CA) and a Company Secretary (CS).




# Industry Landscape

- Market Opportunity
- Factors Driving Industry Growth

03

# Markets Opportunity





# **Factors Driving Industry Growth**



# Drug Discovery & Development

Increasing demand for new drug innovations, growth in biologics and vaccine products development, and increasing regulations in pharma and biotech industry

Specialized knowledge, skills and testing tools that CROs can provide

### Food Testing

Growing international food regulations, evolving Indian food safety regulations, growing world population, and increasing demand for independent third-party inspection & testing

# Electrical & Electronics Testing

Surge in demand for certification services of electrical & electronic products, growing defence budgets and make in India initiatives

Green push by Government for electrical vehicles

# Environment Testing

Increase in regulations to address the growing concerns of air, water and soil contamination

### Diagnostics

Health risks from communicable diseases, life style diseases, growing population and urbanization is driving the demand for precise diagnostic testing

Growing demand in wellness segment



# Our Competitive Advantage

- Our Position in the CRTO Landscape
- Our Strength

04

## Our Position in the CRTO Landscape



### 1 Pharma Analytical & Preclinical

#1 in India

Customers - 90% of India top 20

30% revenues from overseas

### Clinical Research

Among the most reputed CROs in India

80% of revenues from overseas

### 3 Clinical Diagnostics

Among leading labs in TS, AP, UP states

### 5 Food Testing

#1 in India

Customers - 70% of India top 10

### 6 Environment

Among top 5 in India

Customers - PSUs, large corporations across industries

### Electronics & Electricals

Start-up

# Our Strengths

### **QUALITY**

Long & successful regulatory track record - cGMP, GLP, GCP

# CUSTOMER CENTRICITY

Long term partnerships with customers

### **INFRASTRUCTURE**

Unparalleled lab infrastructure in the country. Gold LEED certified Vivarium

### **KNOWLEDGE**

Multi-disciplinary, knowledgeable, skilled and trained manpower

### TECHNOLOGY

Wide range of current technologies with expandable capacities





# Way Forward

Our Key Growth Drivers & Strategies

05

# Our Key Growth Drivers & Strategies



### Favourable markets

- ✓ Growth momentum in markets
- ✓ Growing demand for safe & quality drugs, food, diagnostics, electronics & clean environment

### Core business strategies

- ✓ Capacity expansions
- ✓ Service innovations
- ✓ Penetration into new markets
- ✓ Customer partnerships

### Core operational strategies

- ✓ Operational excellence
- ✓ Hiring right talent
- ✓ Quality & compliance culture
- Cutting edge technologies

### **Best practices**

- ✓ Good corporate governance
- ✓ Risk management
- Listening to customers' needs
- ✓ Continuous learning

We aspire to reach revenues of >Rs.500 cr by 2025/2026



# Thank You

July 2023



#### VIMTA LABS LIMITED

#### **Registered Office**

Plot Number 142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051

NSE: VIMTALABS, BSE: 524394

ISIN: INE579C01029
Website: www.Vimta.com

#### INVESTOR RELATIONS AT



Vimta Labs Ltd.

Narahai Naidu Dodda, CFO Narahai.Dodda@vimta.com



Rahul Thakur Rahul.Thakur@in.ey.com Advait Bhadekar Advait.Bhadekar@in.ey.com